Structure-based Engineering of Species Selectivity in the Interaction between Urokinase and Its Receptor: IMPLICATION FOR PRECLINICAL CANCER THERAPY
about
Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applicationsIsothiocyanate-Functionalized Bifunctional Chelates and fac-[M(I)(CO)3](+) (M = Re, (99m)Tc) Complexes for Targeting uPAR in Prostate CancerMapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallographySelective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammationCleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in miceTumour microenvironments induce expression of urokinase plasminogen activator receptor (uPAR) and concomitant activation of gelatinolytic enzymes.GPIHBP1, an endothelial cell transporter for lipoprotein lipase.Protein-binding RNA aptamers affect molecular interactions distantly from their binding sitesConformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction.Expression of C4.4A, a structural uPAR homolog, reflects squamous epithelial differentiation in the adult mouse and during embryogenesisA new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interactionMimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor.Urokinase-type plasminogen activator receptor (uPAR)-mediated regulation of WNT/β-catenin signaling is enhanced in irradiated medulloblastoma cells.A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogenUrokinase-type plasminogen activator-like proteases in teleosts lack genuine receptor-binding epidermal growth factor-like domains.Small Molecules Engage Hot Spots through Cooperative Binding To Inhibit a Tight Protein-Protein Interaction.A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR)The acidic domain of the endothelial membrane protein GPIHBP1 stabilizes lipoprotein lipase activity by preventing unfolding of its catalytic domain.The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single targetUrokinase plasminogen activator receptor (uPAR) targeted nuclear imaging and radionuclide therapyuPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection.A novel tumor targeting drug carrier for optical imaging and therapyRadiometallated peptides targeting guanylate cyclase C and the urokinase-type plasminogen activator receptor.Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic.Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist.Improved positron emission tomography imaging of glioblastoma cancer using novel 68Ga-labeled peptides targeting the urokinase-type plasminogen activator receptor (uPAR).GPIHBP1 missense mutations often cause multimerization of GPIHBP1 and thereby prevent lipoprotein lipase binding.Common structural traits for cystine knot domain of the TGFβ superfamily of proteins and three-fingered ectodomain of their cellular receptors.Urokinase receptor cleavage correlates with tumor volume in a transgenic mouse model of breast cancer.
P2860
Q26865306-B72E3B47-C45A-4AE7-A55D-4E21F33F01A9Q28821362-73756AB8-903F-4FA3-9F90-96727BC6A91DQ30380709-451AC56E-DE0E-4779-9B54-4BD5C2A81D46Q30496585-1A22D808-82E4-4429-BD59-344FCD7EC745Q33709060-080D1D84-7E5B-4405-98B2-DC538792FB6CQ33974535-9E85914B-9423-4CC8-894C-83CAA87476CDQ34089936-D6F6C3B6-29AF-4896-8707-7366E9E290BFQ34208235-6D501BC1-9C0D-44C7-96F1-877511F0CB86Q35203415-CBEC5B18-440B-4C22-BA03-85762FBA84F8Q35312973-2C61649C-3023-46E7-A4E2-BD86A607C8BCQ35440794-F5C71F89-01B3-4FFF-B566-B1E86CD74B43Q35559411-DA169925-6AFF-4B9C-AA1E-A465024982E1Q35604600-B5C7EA02-4050-44A2-BA91-EADE3BB40002Q36016967-105CB130-E651-4937-BD27-893042BC186CQ36059078-CFEB32BA-5EC1-41CA-9E5E-1A421D413B89Q36201781-8E38DCB3-225A-42E3-B942-76DB75119671Q36276812-6E1976DC-001C-422E-B93B-C27F14B214BCQ36298409-0DF39F7D-439D-421A-A336-7F57591B8664Q36585939-4D6606C9-BDD3-4DD3-B548-19568B092DD9Q36997621-12EC769D-9CC8-41DB-A17D-2944E44D304EQ36997627-1D6F78F1-C1D7-4D9B-991A-F455E4419CE3Q37435242-D2447144-DD75-4920-9F3A-2DB628097106Q37695404-2CA1B3BD-30F9-4A44-86F0-BD7E24BFC3EEQ37783622-EA85C0D9-2B0F-4968-B8DB-F9229F7C29C1Q37895294-11BEB23E-BE95-4582-B51E-3B04EBC8E4DDQ38120755-F25E4456-571B-4BE8-9C36-5BF2D2BFEFACQ38711633-B7FAADBC-8CE3-4059-9623-A4EF2D78AE96Q41877871-F8FB45E4-6511-4E8A-BA27-8B0C2F018F3BQ43677137-F68BE24B-240F-4166-8DC8-90898A308B94Q52956238-8C871DD9-7F95-4ABA-AFB0-E63355382A7C
P2860
Structure-based Engineering of Species Selectivity in the Interaction between Urokinase and Its Receptor: IMPLICATION FOR PRECLINICAL CANCER THERAPY
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Structure-based Engineering of ...... FOR PRECLINICAL CANCER THERAPY
@ast
Structure-based Engineering of ...... FOR PRECLINICAL CANCER THERAPY
@en
Structure-based Engineering of ...... FOR PRECLINICAL CANCER THERAPY
@nl
type
label
Structure-based Engineering of ...... FOR PRECLINICAL CANCER THERAPY
@ast
Structure-based Engineering of ...... FOR PRECLINICAL CANCER THERAPY
@en
Structure-based Engineering of ...... FOR PRECLINICAL CANCER THERAPY
@nl
prefLabel
Structure-based Engineering of ...... FOR PRECLINICAL CANCER THERAPY
@ast
Structure-based Engineering of ...... FOR PRECLINICAL CANCER THERAPY
@en
Structure-based Engineering of ...... FOR PRECLINICAL CANCER THERAPY
@nl
P2093
P2860
P356
P1476
Structure-based Engineering of ...... FOR PRECLINICAL CANCER THERAPY
@en
P2093
Michael Ploug
Mingdong Huang
P2860
P304
P356
10.1074/JBC.M109.093492
P407
P577
2010-04-02T00:00:00Z